Developing therapeutically more efficient Neurturin variants for treatment of Parkinson's disease

• Published in: Neurobiology of disease Vol. 96; pp. 335 - 345
• Main Authors: Runeberg-Roos, Pia, Piccinini, Elisa, Penttinen, Anna-Maija, Mätlik, Kert, Heikkinen, Hanna, Kuure, Satu, Bespalov, Maxim M., Peränen, Johan, Garea-Rodríguez, Enrique, Fuchs, Eberhard, Airavaara, Mikko, Kalkkinen, Nisse, Penn, Richard, Saarma, Mart
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2016; Elsevier
• Subjects: Amphetamine - pharmacology; Animals; CHO Cells; Cricetulus; Disease Models, Animal; Drug Design; GDNF; Genetic Variation - genetics; GFRα1; GFRα2; Growth factor; Heparan sulfate; Heparin; Humans; Macaca fascicularis; Male; Models, Molecular; Neurology; Neurturin; Neurturin - chemistry; Neurturin - genetics; Neurturin - metabolism; NRTN; Oxidopamine - toxicity; Parkinson Disease - complications; Parkinson Disease - drug therapy; Parkinson Disease - etiology; Parkinson Disease - metabolism; Parkinson's disease; Proto-Oncogene Proteins c-ret - genetics; Proto-Oncogene Proteins c-ret - metabolism; Rats; Rats, Wistar; RET; Stereotyped Behavior - drug effects; Sympatholytics - toxicity; Tyrosine 3-Monooxygenase - metabolism; RET; Heparan sulfate; Parkinson's disease; IHC; IP; SNpc; Neurturin; pgsA 745 cells; WB; N1–4; P-TYR; OHDA; GDNF; PD; TH; GFRα1; NRTN; MPTP; Heparin; NV1–4; GAPDH; GFRα2; Growth factor; untagged NRTN variants; Glial cell line-Derived Neurotrophic Factor; Western blotting; phosphotyrosine; heparin; GDNF family receptor α2; hydroxydopamine; GDNF family receptor α1; immunoprecipitated; V5-tagged NRTN variants N1–4; Rearranged during Transfection (a transmembrane tyrosine kinase receptor); immunohistochemical; tyrosine hydroxylase; growth factor; substantia nigra pars compacta; heparan sulfate; 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; CHO cells deficient in heparan sulfate from ATCC; neurturin; glyceraldehyde 3-phosphate dehydrogenase

In Parkinson's disease midbrain dopaminergic neurons degenerate and die. Oral medications and deep brain stimulation can relieve the initial symptoms, but the disease continues to progress. Growth factors that might support the survival, enhance the activity, or even regenerate degenerating dop...